At the recent European Society of Breast Imaging (EUSOBI) meeting in Budapest, ScreenPoint Medical launched its medical education programme with a series of workshops entitled ‘The Transpara experience: multi-vendor, evidence-based breast artificial intelligence for mammography.’
Transpara is an AI solution for breast cancer screening that uses deep learning algorithms to automatically detect lesions in 2D and 3D mammograms. The software categorises mammograms on a 10-point scale indicating the level of risk that cancer is present. This examination score can be used to triage examinations and help radiologists to prioritise patients for further investigation. Interactive decision support of suspicious regions assists radiologists with image interpretation.
Studies have shown that Transpara matches the performance of radiologists, so acting as a second opinion to increase diagnostic confidence, accuracy and productivity.
Commercially available 2D, 3D and combination mammography solutions were on display on the ScreenPoint stand, complemented by a series of hands-on masterclass workshops where practitioners could try the product for themselves.
ScreenPoint Medical ceo Nico Karssemeijer said: “The launch of Transpara at EUSOBI shows our strong commitment to the use of commercially-available breast AI.
“Healthcare providers are looking for evidence-based AI solutions that work with a standard IT and mammography infrastructure, so we created these masterclass workshops to demonstrate what Transpara can do in clinical practice right now. This also ties in to the latest scientific studies presented at EUSOBI, which show that it is possible to replace double reading with single reading for those mammograms labelled as almost certainly normal by Transpara.
ScreenPoint Medical won Best New Radiology Vendor in the inaugural Euro Minnie awards 2019.
Picture: ScreenPoint Medical ceo Nico Karssemeijer.
Published on page 16 of the October 2019 issue of RAD Magazine.